4d
Dealbreaker on MSNBeam Base Editor’s Early Data in Rare Liver Disease Tee Up $500M Stock Sale in Tough MarketA Beam Therapeutics gene-editing therapy designed to fix a mutation at the root of a rare liver protein deficiency now has ...
The one-time therapy appears to correct the mutation that causes the disease, known as Alpha-1 antitrypsin deficiency (AATD), ...
While initial study results suggest Beam's technology can correct alpha-1 antitrypsin deficiency's genetic roots, shares fell ...
Early research shows a one-time gene therapy has potential for addressing both the liver and lung disease that patients with ...
The small study in patients with a rare disorder that causes liver and lung damage showed the potential for precisely ...
BEAM-302 "has set the bar for efficacy in this space," William Blair analysts wrote in an investor note on Monday.
Armed with new proof-of-concept data showing that its in vivo base-editing therapy BEAM-302 can correct the gene mutation in ...
The Cambridge-based company touted the data as evidence of the first successful use of CRISPR gene editing to fix a ...
Proton Beam Therapy is highly effective for treating tumours in sensitive areas, since by reducing exposure of healthy ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results